Clinical Trials Directory

Trials / Terminated

TerminatedNCT05049642

Effect of Chitosan-N-acetylcysteine on Subjective Pain Sensation in Corneal Abrasion

Effect of Chitosan-N-acetylcysteine (Lacrimera®) on Subjective Pain Sensation in Corneal Abrasion: a Pilot Study

Status
Terminated
Phase
N/A
Study type
Interventional
Enrollment
30 (actual)
Sponsor
Vienna Institute for Research in Ocular Surgery · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Aim of this study is to investigate the effect of Chitosan-N-acetylcysteine (C-NAC; Lacrimera®, Croma-Pharma GmbH, Leobendorf, Austria) in patients with corneal abrasion less than one third of the corneal surface on subjective pain sensation.

Detailed description

Commonly, standard of care for corneal abrasion is topical antibiotics. Bandage contact lenses may be used in addition, which significantly decrease pain sensation in a vast majority of patients. Recently, a new preservative-free agent consisting of a novel biopolymer, Chitosan-N-acetylcysteine (C-NAC; Lacrimera®, Croma-Pharma GmbH, Leobendorf, Austria) has been approved for the treatment of dry eye syndrome (DES). This agent electrostatically binds to the mucine layer of the tear film, forming a glycocalyx-like structure. In an animal model, the beneficial effect of Chitosan-N-Acetylcysteine on recovery time has been observed. Aim of this study is to investigate the effect of Chitosan-N-acetylcysteine (C-NAC; Lacrimera®, Croma-Pharma GmbH, Leobendorf, Austria) in patients with corneal abrasion less than one third of the corneal surface on subjective pain sensation. It will further explore the extend of corneal healing after use of Lacrimera® over 5 days in those patients initially treated with Lacrimera®.

Conditions

Interventions

TypeNameDescription
DEVICELacrimeraA new preservative-free formulation of eye drops consists of a novel biopolymer, chitosan-N-acetylcysteine (C-NAC; Lacrimera®, Croma-Pharma GmbH, Leobendorf, Austria), which electrostatically binds to the mucine layer of the tear film forming a glycocalyx-like structure.

Timeline

Start date
2021-05-12
Primary completion
2021-08-31
Completion
2021-08-31
First posted
2021-09-20
Last updated
2021-09-20

Locations

1 site across 1 country: Austria

Source: ClinicalTrials.gov record NCT05049642. Inclusion in this directory is not an endorsement.